Cargando…

Hepatic arterial infusion chemotherapy with or without lenvatinib for unresectable cholangiocarcinoma: a single-center retrospective study

AIM: The purpose of this study is to compare the efficacy and safety of hepatic arterial infusion chemotherapy (HAIC) of oxaliplatin, fluorouracil and leucovorin (FOLFOX) plus lenvatinib and FOLFOX-HAIC alone in patients with unresectable cholangiocarcinoma. PATIENTS & METHODS: Retrospective ana...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Yajing, Wei, Zhanqi, Zhang, Zheng, Xu, Jingyi, Wang, Yaqin, Chen, Qian, Zhang, Yuewei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Future Medicine Ltd 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10577516/
https://www.ncbi.nlm.nih.gov/pubmed/37850031
http://dx.doi.org/10.2217/hep-2023-0006
_version_ 1785121343003426816
author Wang, Yajing
Wei, Zhanqi
Zhang, Zheng
Xu, Jingyi
Wang, Yaqin
Chen, Qian
Zhang, Yuewei
author_facet Wang, Yajing
Wei, Zhanqi
Zhang, Zheng
Xu, Jingyi
Wang, Yaqin
Chen, Qian
Zhang, Yuewei
author_sort Wang, Yajing
collection PubMed
description AIM: The purpose of this study is to compare the efficacy and safety of hepatic arterial infusion chemotherapy (HAIC) of oxaliplatin, fluorouracil and leucovorin (FOLFOX) plus lenvatinib and FOLFOX-HAIC alone in patients with unresectable cholangiocarcinoma. PATIENTS & METHODS: Retrospective analysis of patients receiving FOLFOX-HAIC with or without lenvatinib. RESULTS: Forty-one patients were included, with 22 patients receiving HAIC alone and 19 patients receiving HAIC plus lenvatinib. Combination treatment significantly prolonged overall survival and progression-free survival compared with HAIC alone. Grade 1–2 adverse events were more frequent in the combination group but manageable. No severe AEs or treatment-related deaths were reported. CONCLUSION: FOLFOX-HAIC plus lenvatinib has the potential to be a treatment option for unresectable cholangiocarcinoma.
format Online
Article
Text
id pubmed-10577516
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Future Medicine Ltd
record_format MEDLINE/PubMed
spelling pubmed-105775162023-10-17 Hepatic arterial infusion chemotherapy with or without lenvatinib for unresectable cholangiocarcinoma: a single-center retrospective study Wang, Yajing Wei, Zhanqi Zhang, Zheng Xu, Jingyi Wang, Yaqin Chen, Qian Zhang, Yuewei Hepat Oncol Research Article AIM: The purpose of this study is to compare the efficacy and safety of hepatic arterial infusion chemotherapy (HAIC) of oxaliplatin, fluorouracil and leucovorin (FOLFOX) plus lenvatinib and FOLFOX-HAIC alone in patients with unresectable cholangiocarcinoma. PATIENTS & METHODS: Retrospective analysis of patients receiving FOLFOX-HAIC with or without lenvatinib. RESULTS: Forty-one patients were included, with 22 patients receiving HAIC alone and 19 patients receiving HAIC plus lenvatinib. Combination treatment significantly prolonged overall survival and progression-free survival compared with HAIC alone. Grade 1–2 adverse events were more frequent in the combination group but manageable. No severe AEs or treatment-related deaths were reported. CONCLUSION: FOLFOX-HAIC plus lenvatinib has the potential to be a treatment option for unresectable cholangiocarcinoma. Future Medicine Ltd 2023-09-29 /pmc/articles/PMC10577516/ /pubmed/37850031 http://dx.doi.org/10.2217/hep-2023-0006 Text en © 2023 Yuewei Zhang https://creativecommons.org/licenses/by-nc-nd/4.0/This work is licensed under the Attribution-NonCommercial-NoDerivatives 4.0 Unported License (https://creativecommons.org/licenses/by-nc-nd/4.0/)
spellingShingle Research Article
Wang, Yajing
Wei, Zhanqi
Zhang, Zheng
Xu, Jingyi
Wang, Yaqin
Chen, Qian
Zhang, Yuewei
Hepatic arterial infusion chemotherapy with or without lenvatinib for unresectable cholangiocarcinoma: a single-center retrospective study
title Hepatic arterial infusion chemotherapy with or without lenvatinib for unresectable cholangiocarcinoma: a single-center retrospective study
title_full Hepatic arterial infusion chemotherapy with or without lenvatinib for unresectable cholangiocarcinoma: a single-center retrospective study
title_fullStr Hepatic arterial infusion chemotherapy with or without lenvatinib for unresectable cholangiocarcinoma: a single-center retrospective study
title_full_unstemmed Hepatic arterial infusion chemotherapy with or without lenvatinib for unresectable cholangiocarcinoma: a single-center retrospective study
title_short Hepatic arterial infusion chemotherapy with or without lenvatinib for unresectable cholangiocarcinoma: a single-center retrospective study
title_sort hepatic arterial infusion chemotherapy with or without lenvatinib for unresectable cholangiocarcinoma: a single-center retrospective study
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10577516/
https://www.ncbi.nlm.nih.gov/pubmed/37850031
http://dx.doi.org/10.2217/hep-2023-0006
work_keys_str_mv AT wangyajing hepaticarterialinfusionchemotherapywithorwithoutlenvatinibforunresectablecholangiocarcinomaasinglecenterretrospectivestudy
AT weizhanqi hepaticarterialinfusionchemotherapywithorwithoutlenvatinibforunresectablecholangiocarcinomaasinglecenterretrospectivestudy
AT zhangzheng hepaticarterialinfusionchemotherapywithorwithoutlenvatinibforunresectablecholangiocarcinomaasinglecenterretrospectivestudy
AT xujingyi hepaticarterialinfusionchemotherapywithorwithoutlenvatinibforunresectablecholangiocarcinomaasinglecenterretrospectivestudy
AT wangyaqin hepaticarterialinfusionchemotherapywithorwithoutlenvatinibforunresectablecholangiocarcinomaasinglecenterretrospectivestudy
AT chenqian hepaticarterialinfusionchemotherapywithorwithoutlenvatinibforunresectablecholangiocarcinomaasinglecenterretrospectivestudy
AT zhangyuewei hepaticarterialinfusionchemotherapywithorwithoutlenvatinibforunresectablecholangiocarcinomaasinglecenterretrospectivestudy